MAM
Future Generali India Insurance celebrates Pride Month with creative zeal
Mumbai: Reinforcing its stance as a strong ally to the LGBTQIA+ community, Future Generali India Insurance Company Ltd (FGII), has taken the PRIDE celebrations a notch higher this year by throwing the doors open to all allies of the community. The company, which has been organising PRIDE celebrations across its offices in India for the past two years, has moved beyond its workplace and has tied up with the renowned theatre group Tamaasha for the exclusive screening of “Be-loved” – a play on and by the people from the community.
In line with its strategic vision of embedding DEI (Diversity, Equity and Inclusion) into its culture, not only as an inclusive insurer and employer but also as an inclusive corporate citizen, FGII has partnered with Humsafar Trust for providing education and skill-building support to LGBTQIA+ individuals in Mumbai, Maharashtra. It has handed over a cheque of Rs 17 lakh to Humsafar Trust to provide support with English-speaking courses, training in computers etc for individuals from within the community to enhance their employability.
Since the last two years, FGII has been celebrating PRIDE month in support to the community with a series of events, workshops and PRIDE parade at its offices across India. This has helped FGII in sensitising employees and generate awareness regarding LGBTQIA+ issues with a view towards normalising the conversation at the workplace and providing a conducive environment for colleagues from the community.
Screened at the Royal Opera House in Mumbai, the production – “Be-Loved,” explored queer love and companionship through theatre, music, poetry, and movement and delved into desi stories of love, connection, and family, showcasing the rich cultural contributions of the LGBTQIA+ community. Some of the noteworthy guests who attended the event included Shreegauri Sawant, a transgender activist; Trinetra Haldar, actor and Karnataka’s first transgender doctor and Bani J, Indian VJ and actress, among others.
Speaking about the pride event, Future Generali India Insurance Company Ltd. MD & CEO Anup Rau said, “This year, by taking pride beyond our offices, we aimed to reach a larger audience for education and sensitization. We think it’s great to showcase performances and queer stories, enacted by queer individuals, with most of the crew from the community. It’s a celebration more than anything else! The response to the show has been phenomenal and we will continue with our efforts to drive acceptance and belonging for the community.”
“At Future Generali, we are driven by our commitment to LGBTQIA+ rights as an inclusive employer, insurer, and corporate citizen. We’ve revolutionized our workplace culture and led the industry by being the first in India to include LGBTQIA+ and same-sex partners in our retail health insurance products. Our partnership with Humsafar Trust takes this further, providing crucial education and skill-building support to LGBTQIA+ individuals in Mumbai. Together, we’re forging a path towards a more inclusive and empowered future,” Rau added.
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
